This session will describe the changing therapeutic landscape for patients with chronic lymphocytic leukemia (CLL) and the integration of these novel agents into the treatment paradigm. The discussion will include management issues that arise with the novel agents, including atrial fibrillation, bleeding, diarrhea/colitis, and tumor lysis syndrome.
Richard R. Furman, MD, Weill Cornell Medical College
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members